Daehan Nupharm Co.,Ltd. (KOSDAQ:054670)
South Korea · Delayed Price · Currency is KRW 7,150.00
-150.00 (-2.05%)
At close: Apr 21, 2026
Daehan Nupharm Revenue
In the year 2025, Daehan Nupharm had annual revenue of 202.40B KRW with 0.11% growth. Daehan Nupharm had revenue of 51.79B in the quarter ending December 31, 2025, with 1.59% growth.
Revenue
202.40B
Revenue Growth
+0.11%
P/S Ratio
0.50
Revenue / Employee
887.73M
Employees
228
Market Cap
100.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 202.40B | 214.78M | 0.11% |
| Dec 31, 2024 | 202.19B | -2.04B | -1.00% |
| Dec 31, 2023 | 204.22B | 6.27B | 3.16% |
| Dec 31, 2022 | 197.96B | 31.37B | 18.83% |
| Dec 31, 2021 | 166.59B | 17.29B | 11.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ahn-Gook Pharmaceutical | 306.87B |
| Cosmax Nbt | 287.48B |
| H.PIO | 258.19B |
| Sinsin Pharmaceutical | 113.78B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 106.44B |
| Sam-A Pharm. | 77.80B |
| Polaris AI Pharma | 63.94B |
| Samik Pharmaceutical Company LTD. | 60.02B |